SOURCE: MMIT Analytics, as of June 22, 2018
Tuesday, June 26, 2018
Preferred-tier access to...
...the eczema medication Eucrisa has grown 95% since June 2017, to
39 million lives. The FDA approved the drug in December 2016, and manufacturer
Pfizer has been promoting it as a competitor to Regeneron's Dupixent since
then. Dupixent holds preferred-tier status for 92 million covered lives.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment